Gilead Reduces Prices for Viread® and Truvada® in the Developing World
Gilead Sciences, Inc. announced a significant price reduction for Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) made available through the company's Access Program in the developing world. Both once-a-day antiretroviral medications for HIV are available at no-profit prices in 97 developing countries around the world through this program.
The price decreases announced are due to increased economies of scale, production at a new plant in the Bahamas that manufactures active pharmaceutical ingredient for both Viread and Truvada, and continued improvements in the manufacturing process. As a result of these changes, Viread and Truvada are now priced at US$17.00 and US$26.25 for a 30-day supply, or $0.57 and $0.87 per day, respectively, for private and public programs treating people with HIV/AIDS in the 97 nations of the program. The new prices represent approximately a 31 percent and 12 percent reduction in the no-profit prices for Viread and Truvada, respectively.
Most read news
Organizations
Other news from the department research and development
These products might interest you

AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification

Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.